Furthermore, treating Kasumi-1 cells for 24 h with FTY720 could decrease the protein level of AML1-ETO (Figure 7G), a fusion oncoprotein, which is the most common cytogenetic subtype of AML. This evidence concerns the gene RUNX1 and acute myeloid leukemia.